/
Other
Efficacy and Safety
209
Pipeline Programs↗
277
Active Trials↗
347
Companies Involved↗
Efficacy and Safety is a highly competitive landscape with 209 programs across 347 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., Chong Kun Dang Pharmaceutical, Qilu Pharmaceutical Co., Ltd.. 93 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Haisco Pharmaceutical Group Co., Ltd.
3 programs
Chong Kun Dang Pharmaceutical
2 programs
Qilu Pharmaceutical Co., Ltd.
2 programs
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2 programs
Amgen
2 programs
Innovent Biologics Technology Limited (Shanghai R&D Center)
2 programs
Pipeline
Programs by Phase
Preclinical44
Phase 14
Phase 268
Phase 393
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
165 of 203 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 203 classified programs, each share of the total. Modality classified for 100% of 209 pipeline programs.
Analysis
Trial Status
2,246
clinical trials
Completed1,428 · 64%
Unknown status319 · 14%
Terminated153 · 7%
Recruiting132 · 6%
Not yet recruiting89 · 4%
Withdrawn64 · 3%
Other61 · 3%
Clinical Trials
Trial Activity
2246 trials
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06838949·80 enrolled
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
Recruiting·—·N/A·NCT06479291·126 enrolled
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 2·NCT07275840·800 enrolled
Page 1 of 150
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)